Literature DB >> 34966540

A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas.

Brian I Carr1, Harika Gozukara Bag2, Volkan Ince1,3, Zeki Ogut3, Adem Tuncer3, Sami Akbulut3, Veysel Ersan1,3, Sertac Usta1,3, Burak Isik1,3, Sezai Yilmaz1,3.   

Abstract

OBJECTIVES: The majority of HCCs present at an advanced stage in which potentially curative therapies cannot be used. Surveillance ultrasound has been found to increase the numbers of patients diagnosed with small tumors, but it is often not used. We aimed to try to identify widely-available and cheap potential serum markers for use in patients at risk for HCC.
MATERIAL AND METHODS: A comparison was made of the complete blood count and liver function tests in a group of patients (n=114) with proven small HCCs (≤ 2 cm) and patients without HCC (n=506), all of whom were treated by liver transplantation in our Liver Transplantation Institute.
RESULTS: Significant differences were found for blood levels of WBC, lymphocytes, total bilirubin and transaminases. Several 2-parameter combinations were assessed, but only the combination of total bilirubin and lymphocytes was found to be significantly different between patients with small HCCs and no HCC. Multivariate regression analysis showed significance only for total bilirubin levels and lymphocyte counts. The results were confirmed using a separate small cohort of non-transplant patients.
CONCLUSION: The combination of elevated levels of total bilirubin and lymphocyte counts holds promise for identification of patients with chronic liver disease who are at risk for HCC.

Entities:  

Keywords:  hepatocellular carcinoma; liver transplanty; lymphocyte; potential biomarkers; total bilirubin

Year:  2021        PMID: 34966540      PMCID: PMC8714058     

Source DB:  PubMed          Journal:  Clin Pract (Lond)        ISSN: 2044-9038


  10 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

2.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.

Authors:  Petr Pancoska; Sheng-Nan Lu; Brian I Carr
Journal:  J Gastrointest Dig Syst       Date:  2013-03-02

4.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Small hepatocellular carcinomas and thrombocytopenia.

Authors:  Brian I Carr; Vito Guerra; Massimo De Giorgio; Stefano Fagiuoli; Petr Pancoska
Journal:  Oncology       Date:  2012-09-18       Impact factor: 2.935

7.  Staging systems in hepatocellular carcinoma.

Authors:  Fernando Pons; Maria Varela; Josep M Llovet
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

8.  Monofocal hepatocellular carcinoma: How much does size matter?

Authors:  Filippo Pelizzaro; Barbara Penzo; Giulia Peserico; Angela Imondi; Anna Sartori; Alessandro Vitale; Umberto Cillo; Edoardo G Giannini; Antonella Forgione; Gian Ludovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Rodolfo Sacco; Giuseppe Cabibbo; Fabio Marra; Andrea Mega; Filomena Morisco; Antonio Gasbarrini; Gianluca Svegliati-Baroni; Francesco Giuseppe Foschi; Andrea Olivani; Alberto Masotto; Gerardo Nardone; Giovanni Raimondo; Francesco Azzaroli; Gianpaolo Vidili; Filippo Oliveri; Franco Trevisani; Fabio Farinati
Journal:  Liver Int       Date:  2020-11-23       Impact factor: 5.828

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.